Dupret-Bories A.,CHU Hautepierre |
Vergez S.,Toulouse University Hospital Center |
De Bonnecaze G.,Toulouse University Hospital Center |
Decotte A.,Toulouse University Hospital Center |
Serrano E.,Toulouse University Hospital Center
B-ENT | Year: 2013
Objective: 1) To evaluate the effectiveness and side-effects of endoscopic surgical treatment for maxillary sinus fungus balls, and to describe approaches to limiting recurrence of the disease and surgical complications. 2) To compare the results of this nasal endoscopic treatment with the results of treatment using a vestibular approach to the anterior wall of the maxillary sinus as described in the literature. Patients and methods: An institutional retrospective review was conducted for patients undergoing treatment for a maxillary sinus fungus ball using endonasal surgery alone from January 2005 to December 2010. Results: A total of 100 patients were included in the study (58 women and 42 men, average age 54 years). The median follow-up time was 32 months. Three patients had a recurrence after our team performed endonasal surgery. No patients experienced complications. Conclusion: Our results are consistent with previous findings, indicating that the postoperative complication rate for endonasal surgery is low by comparison with the vestibular approach. Both techniques have similar outcomes. The nasal endoscopic route offers similar rates of success with a negligible complication rate.
Soussan M.,University of Paris 13 |
Rust E.,CHU Hautepierre |
Pop G.,University of Paris 13 |
Morere J.-F.,University of Paris 13 |
And 2 more authors.
Insights into Imaging | Year: 2012
Objective: We aimed to describe a pattern of rim uptake observed in lung infarction on FDG-PET/CT, called the "rim sign." It was defined as a continuous slight FDG uptake along the border of a subpleural consolidation without uptake within the consolidation. Methods: We retrospectively reviewed the FDG-PET/CT studies of 400 patients referred for thoracic oncological workup from November 2010 to July 2011. The rim sign was observed in six patients who had confirmed pulmonary infarction (PI) on MDCT showing acute pulmonary embolism (n = 4) or tumoral arterial obstruction (n = 2). Results: Eight PIs in the six patients exhibited the rim sign with slight uptake (median SUVmax: 3. 6, 2. 2-6. 8) and median size of 48. 5 mm (30-74). On MDCT, central lucencies, triangular shape and vessel sign were observed in 5/8, 4/8 and 1/8 cases, respectively. Two out of the eight PIs exhibited only the rim sign and none the suggestive MDCT sign. Conclusion: The rim sign is easily recognisable at FDG-PET/CT and is strongly suggestive of PI. This pattern can be observed even in the absence of suggestive findings on MDCT. Recognition of this sign should prompt investigations for pulmonary embolism. Main Messages: • The rim sign is a slight FDG uptake around an area of subpleural consolidation• The rim sign is strongly suggestive of pulmonary infarction• Recognition of the rim sign should prompt investigations for pulmonary embolism © 2012 The Author(s).
Bykerk V.P.,Inammatory Arthritis Center |
Kstr A.J.,Addenbrookes Hospital |
Alvaro-Gracia J.,Hospital Universitario Of La Princesa |
Pavelka K.,Charles University |
And 8 more authors.
Annals of the Rheumatic Diseases | Year: 2012
Objective: To evaluate the safety and efficacy of tocilizumab in clinical practice in patients with rheumatoid arthritis (RA) with inadequate responses (IR) to disease-modifying antirheumatic drugs (DMARDs) or both DMARDs and tumour necrosis factor α inhibitors (TNFis). Methods: Patients-categorised as TNFi-naive, TNFi-previous (washout) or TNFi-recent (no washout)-received open-label tocilizumab (8 mg/kg) every 4 weeks ± DMARDs for 24 weeks. Adverse events (AEs) and treatment discontinuations were monitored. Efficacy end points included American College of Rheumatology (ACR) responses, 28-joint disease activity score (DAS28) and European League Against Rheumatism responses. Results: Overall, 1681 (976 TNF-naive, 298 TNFiprevious and 407 TNFi-recent) patients were treated; 5.1% discontinued treatment because of AEs. The AE rate was numerically higher in TNFi-recent (652.6/100 patient-years (PY)) and TNFi-previous (653.6/100PY) than in TNFi-naive (551.1/100PY) patients. Serious AE rates were 18.0/100PY, 28.0/100PY and 18.6/100PY; serious infection rates were 6.0/100PY, 6.8/100PY and 4.2/100PY, respectively. At week 4, 36.5% of patients achieved ACR20 response and 14.9% DAS28 remission (<2.6); at week 24, 66.9%, 46.6%, 26.4% and 56.8% achieved ACR20/ACR50/ACR70 responses and DAS28 remission, respectively. Overall, 61.6% (TNFi-naive), 48.5% (TNFiprevious) and 50.4% (TNFi-recent) patients achieved DAS28 remission. Conclusions: In patients with RA who were DMARD-IR/TNFi-IR, tocilizumab ± DMARDs provided rapid and sustained efficacy without unexpected safety concerns.
Meugnier E.,University of Lyon |
Meugnier E.,Center Hospitalier Lyon Sud |
Meugnier E.,French Institute of Health and Medical Research |
Meugnier E.,French National Institute for Agricultural Research |
And 18 more authors.
Physiological Genomics | Year: 2011
The efficacy of anti-TNF-α therapies highlights the role of TNF-α in the pathogenesis of rheumatoid arthritis (RA). However, the mechanism of action of these agents is poorly understood at the molecular level. The aim of this study was to characterize the effects of anti-TNF-α treatment on the global gene expression profile in peripheral blood mononuclear cells (PBMCs) of responder RA patients. Changes in gene expression were determined using oligonucleotide microarrays (25,341 genes) in PBMCs obtained before and after 12 wk of treatment with either etanercept or adalimumab from responder RA patients. Two hundred fifty-one genes displayed significant changes (false discovery rate < 0.1%) in expression level (178 upregulations with mean fold change= 1.5 and 73 downregulations with mean fold change =-1.50) after 12 wk of treatment. Importantly, the expression of several genes, including those coding for the calcium binding proteins S100A12 and A8, CD14 antigen, Selectin P, or ribosomal protein L39, reported to be upregulated in RA patients, were found to be decreased after anti-TNF-α treatment. Globally, inflammation, immune response, apoptosis, protein synthesis, and mitochondrial oxido-reduction were the most affected pathways in response to anti-TNF-α treatment. The obtained gene expression signature in PBMCs provides new information to better understand the mechanisms of action of anti-TNF-α treatment in RA patients. © 2011 the American Physiological Society.
Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice
Bykerk V.P.,Inflammatory Arthritis Center |
Ostor A.J.K.,University of Cambridge |
Alvaro-Gracia J.,Hospital Universitario Of La Princesa |
Pavelka K.,Institute of Rheumatology |
And 8 more authors.
Clinical Rheumatology | Year: 2015
This was an exploratory analysis comparing the safety and efficacy of tocilizumab monotherapy with those of tocilizumab in combination with disease-modifying anti-rheumatic drugs (DMARDs). Data were from a single-arm, nonrandomized, open-label, 24-week study in patients with rheumatoid arthritis in which patients with inadequate responses to DMARDs or tumor necrosis factor-α inhibitors received tocilizumab 8 mg/kg intravenously every 4 weeks plus methotrexate/other DMARD(s) combination therapy. If they were intolerant of methotrexate/other DMARD, patients received tocilizumab monotherapy. Effectiveness endpoints included American College of Rheumatology (ACR) responses (ACR20/50/70/90) and disease activity score using 28 joints (DAS28). Of 1,681 patients, 239 received tocilizumab monotherapy, and 1,442 received combination therapy. Methotrexate was the most common DMARD (79 %) used in combination therapy. The frequency of adverse events (AEs), serious AEs, and AEs leading to withdrawal were similar between tocilizumab monotherapy (82.4, 7.9, and 5.4 %, respectively) and combination therapy (76.6, 7.8, and 5.1 %, respectively). No differences in ACR20/50/70/90 responses were observed between treatment groups (66.9 %/43.5 %/23.8 %/10.0 % vs 66.9 %/47.2 %/26.8 %/8.5 %, respectively; p > 0.12 for all individual comparisons, including ACR50 propensity score analyses). The decrease in DAS28 was also similar between treatment groups (mean ± standard deviation: −3.41 ± 1.49 for tocilizumab monotherapy vs −3.43 ± 1.43 for combination therapy; p > 0.33 all analyses, including propensity score analyses). Tocilizumab had a comparable safety profile, and was similarly effective, when used as monotherapy or in combination with DMARDs in a broad population of patients with rheumatoid arthritis. © 2015, The Author(s).